All reached patients | No symptomatic improvement | Symptomatic improvement | P values | |
N | 507 | 68 | 408 | |
Follow-up duration in days (median (IQR)) | 757 (465–1139) | 755 (514–1146) | 764 (463–1129) | 0.708 |
Residual impairment (%)* | 190 (38.1) | 68 (100) | 119 (29.2) | <0.001 |
Percentage of main symptom remedied (median (IQR)) | 80 (60–90) | 60 (25–80) | 80 (65–90) | <0.001 |
Main symptom remedied (n (%))† | 208 (68.6) | 28 (66.7) | 165 (68.2) | 0.988 |
Would undergo TAVI again (n (%)) | 428 (89.9) | 56 (86.2) | 348 (90.6) | 0.375 |
Symptomatic improvement defined as decrease in NYHA class after 30 days post-TAVI.
*Residual impairment is defined as not returning to having no functional impairment, that is, NYHA 1, after TAVI procedure.
†Main symptom remedied was defined as a >50% improvement of the main symptom.
NYHA, New York Heart Association; TAVI, transcatheter aortic valve implantation.